Almac Discovery Announces Selection of Preclinical Development Candidate for Its Allosteric Akt Inhibitor Programme.

CRAIGAVON, Northern Ireland--(BUSINESS WIRE)--Almac Discovery is pleased to announce the selection of a preclinical development candidate from its allosteric Akt inhibitor programme. Akt is a key component of the PI3K pathway, one of the major pathways driving tumour growth in many cancer types. ALM301 is a potent, subtype selective Akt1 & Akt2 inhibitor with good pharmacokinetic properties in multiple species, and an excellent selectivity profile over other targets.